...a Business Solution for Better Clinical Drug Development in Serious Unsolved Diseases
Engaging INCLUDING more patients in clinical development:

1) How do we do this right?
2) Where do we go from here?
The Hurdle: Commercial Feasibility

Value = \frac{Benefit}{Cost}

Engagement
Safety Data
Human Mission

Hard Costs
Operational Focus

Regulatory Risks
PR Risks

We shoot too low
The Wide Trial Solution

An independent central platform for sponsoring & managing Expanded Access programs

- Expertise
- Alignment of interest
- Feasibility for all stakeholders
The Wide Trial Solution

Drug Development Tasks by Sector:

Commercial

Non-Profit

Expanded Access
1) Central Non-Profit Platform

2) Charitable Resources

3) Partner Trial Sites and Services

- EAP Sponsor
- CRO
- CTMS
- PVx

4) Secondary Data Assets

- Percent Survival
  - Gene A signature
  - Gene B signature

Jess Rabourn, CFA
September 13, 2016

WIDE Trial
Ax-S Pharma
The Wide Trial Solution

**Costs**

- Hard Costs
- Operational Focus
- PR Risks
- Regulatory Risks

shift shift Reduce! manage
Real World Data / Discoveries in “Pragmatic Setting”

Using Real-World Evidence to Accelerate Safe and Effective Cures
Advancing Medical Innovation for a Healthier America
June 2016

Jess Rabourn, CFA
September 13, 2016
Traditional population-trial design

Phase 1

Phase 2

Phase 3

RCT
The Wide Trial Solution

Expanded Access Benefits

Engagement
Safety Data
Humanity

Clinical Outcomes
The Wide Trial Solution

Value = \frac{Benefit}{Cost}

Engagement  
Safety Data  
Humanity  

+  

Population Knowledge for Targeted Pivotal Trials

Regulatory Risks managed

shifted away  
Hard Costs

shifted away  
Operational Focus

reduced  
PR Risks
Jess Rabourn

jess.rabourn@axspharma.com
+1 (415) 637-4774